number of downloads : ?
language
eng
Author
Harvey N. C. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, UK
Kanis J. A. Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
Oden A. Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
Nakamura T. National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan
Shiraki M. Research Institute and Practice for Involutional Diseases, 1610-1 Meisei, Misato, Azumino, Nagano, 399-8101, Japan
Kuroda T. Medical Affairs Dept., Asahi-Kasei Pharma Corporation, 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo, 101-8101, Japan
Johansson H. Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
McCloskey E. V. Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
Subject
Epidemiology; FRAX; Osteoporosis; Randomised controlled trial; Teriparatide; Vertebral fracture
Journal Title
OSTEOPOROSIS INTERNATIONAL
Volume
26
Issue
9
Start Page
2347
End Page
2353
ISSN
0937-941X
ISSN(Online)
1433-2965
Published Date
2015-09
DOI
PubMed ID
Publisher
SPRINGER LONDON LTD
NII Type
Journal Article
OAI-PMH Set
Faculty of Medicine
Remark
NH has received consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare, and Internis Pharma. JA Kanis has received consulting fees, advisory board fees, lecture fees, and/or grant support from the majority of companies concerned with skeletal metabolism. EVM has received consultancy, lecture fees, research grant support, and/or honoraria from ActiveSignal, Alliance for Better Bone Health, AMGEN, Bayer, Consilient Healthcare, GE Lunar, Hologic, Internis Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Servier, Tethys, UCB, and Univadis. TN received research grants and/or consulting fees from Chugai Pharmaceutical, Teijin Pharma, Asahi Kasei Pharma, and Daiichi Sankyo. MS received consulting fees from Chugai, Daiichi Sankyo, Asahi Kasei Pharma, Teijin Pharma, and MSD. TS received consulting fee and/or research grant from Asahi-Kasei Pharma, Daiichi-Sankyo-Co., Eli Lilly Japan, and Pfizer. TK is an employee of Asahi Kasei Pharma Corporation. Anders Oden and Helena Johansson declare that they have no conflict of interest.